From nobel to no cure: A case for monitoring antibiotic resistance in the gastric pathogen Helicobacter pylori

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 3, 2006, Pages 349-351

  Chisholm, Stephanie A ^a   Owen, Robert J ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH; CIPROFLOXACIN; CLARITHROMYCIN; FURAZOLIDONE; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMYCIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AWARDS AND PRIZES; BACTERIAL STRAIN; BACTERIUM CULTURE; DUODENUM ULCER; EDITORIAL; ENDOSCOPY; ERADICATION THERAPY; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PATIENT COMPLIANCE; PEPTIC ULCER; PRACTICE GUIDELINE; STOMACH BIOPSY; STOMACH ULCER;

DRUG RESISTANCE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; NOBEL PRIZE; PATIENT COMPLIANCE;

EID: 33745208232     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.3.349     Document Type: Editorial

References (18)

1. Graham DY, Lew GM, Malaty HM et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 102, 493-496 (1992).
2. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob. Agents Chemother. 48, 4843-4847 (2004).
3. Lopez-Brea M, Domingo D, Sanchez I, Alarcon T. Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates from Spain. J. Antimicrob. Chemother 40, 279-281 (1997).
4. Prazeres MP, Magalhaes Queiroz DM, Campos Barbosa DV et al. Halicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil. Antimicrob. Agents Chemother. 46, 2021-2023 (2002).
5. Boyanova LR, Nikolov E, Lazarova G et al. Antibacterial resistance in Helicobacter pylori strains isolated from Bulgarian children and adult patients over 9 years. J. Med. Microbiol. 55, 65-68 (2006).
6. Meyer JM, Silliman NP, Wang W et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann. Intern. Med. 136, 13-24 (2002).
7. Osato MS. Antimicrobial susceptibility testing for Helicobacter pylori sensitivity test results and their clinical relevance. Curr. Pharm. Des. 6, 1545-1555 (2000).
8. Wolle K, Leodolter A, Malfertheiner P, Konig W. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J. Med. Microbiol. 51, 705-709 (2002).
9. Gisbert JP, Pajares JM. Helicobacter pylori "rescue" therapy after failure of two eradication treatments. Helicobacter 10, 363-372 (2005).
10. Boyanova LR, Koumanova G, Gergova M et al. Prevalence of resistant Helicobacter pylori isolates in Bulgarian children. J. Med. Microbiol. 51, 786-790 (2002).
11. Tankovic J, Lascols C, Sculo Q, Petit JC, Soussy CJ. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 47, 3942-3944 (2003).
12. Kim JJ, Reddy R, Lee M et al. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J. Antimicrob. Chemother. 47, 459-461 (2001).
13. Mendonca S, Ecclissato C, Sartori MS et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter 5, 79-83 (2000).
14. Godoy AP, Ribeiro, ML, Benvengo YH et al. Analysis of antimicrobiol susceptibility and virulence factors in Helicobacter pylori clinical isolates. BMC. Gastroenterol. 3, 20 (2003).
15. Fujimura S, Kato S, Kawamura T, Watanabe A. In vitro activity of rifampicin against Helicobacter pylori isolated from children and adults. J. Antimicrob. Chemother. 49, 541-543 (2002).
16. Heep M, Beck D, Bayerdorffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob. Agents Chemother. 43, 1497-1499 (1999).
17. Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur. J. Clin. Microbiol. Infect. Dis. 19, 538-541 (2000).
18. Branca GT, Spanu G, Cammarota AM et al. High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy. Int. J. Antimicrob. Agents 24, 433-438 (2004).